Treatment with bacteriophages: regimens, course, and when the method is used

Bacteriophages are bacterial viruses that selectively infect and lyse microbial cells. Phage therapy is attracting attention due to the growing resistance to antibiotics and the ability of phages to work where chemical drugs are weak. However, this method is not universal: the phage spectrum is narrow, requiring selection for a specific strain and high-quality production according to pharmaceutical standards. [1]

International reviews in recent years show a growing number of clinical trials, but the evidence base is still heterogeneous: pilot studies, case series, and early-stage studies predominate. Efficacy depends on the location of the infection, biofilm, drug titer, delivery route, and appropriate combination with antibiotics. [2]

The regulatory environment is changing rapidly. In Europe, the European Pharmacopoeia adopted the general chapter 5.31 on phage-medicinal products in 2024, and in 2025, the EMA published draft quality guidelines for human phage products. This is key to standardizing quality, safety, and batch release. [3]

In the United States, the primary access route is currently through individual expanded access programs under current Food and Drug Administration regulations. These programs allow for the treatment of severe drug-resistant infections when alternatives have been exhausted, while simultaneously accumulating data. [4]

Table 1. Phage therapy: strengths and weaknesses

What does it give?	What limits	How to overcome
Narrow focus and high specificity	A susceptibility test for a specific strain is required.	Rapid phage selection in a reference laboratory
Potential against biofilms	Delivery to the hearth is difficult	Local routes of administration, combination with debridement
Possible synergy with antibiotics	The risk of selecting phage-resistant clones	Cocktails of several phages, rotation, combinations
Low incidence of serious adverse events	Quality and titer standards are needed	Manufacturing according to pharmacopoeial and regulatory requirements
Summary of current reviews and regulatory documents. [5]

What the data shows: where there is already evidence for practice

Systematic reviews and study maps document dozens of registered clinical trials from 2020 to 2024, but large multicenter trials are still scarce. Nevertheless, the safety of phages is being repeatedly confirmed, and clinical responses are more often observed with individualized regimens based on pathogen susceptibility. [6]

In 2024, a randomized, double-blind study of a phage mixture in patients with diabetic foot disease was published. The main finding was acceptable tolerability and safety across various clinical scenarios, which is important for subsequent phases. Evaluation of efficacy requires more precise selection of strains and adequate tissue delivery. [7]

The key principle today is personalization: the pathogen is isolated, a panel of phages is tested, a cocktail is designed for the patient's strain, and it is delivered to the location where the bacteria resides. This approach, with expanded access, has already demonstrated clinical responses in multidrug-resistant Pseudomonas aeruginosa and Acinetobacter infections. [8]

Combination regimens with antibiotics are promising due to the phenomenon of synergy. A growing body of work is exploring phage-antibiotic synergy against Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter, and Escherichia coli, including effects on biofilms and reduction of minimum inhibitory concentrations. [9]

Table 2. Level of confirmation by clinical fields

Localization	What's in store for 2023-2025?	Commentary for practice
Chronic wounds and diabetic foot	Early phase, case series, randomized safety study	Personalization, local delivery, combination with surgery
Respiratory tract infections	Case series in complex patients, on extended access	Aerosol and endobronchial delivery according to indications
Bone and implant infections	Separate series with local instillation after debridement	Long courses, biofilm control, combination with antibiotics
Urogenital infections	Early work, needs standardization	Local instillation, microbiological control
Summary assessment of reviews of ongoing trials and expanded access.[10]

Who and how to select: the patient's path from seeding to cocktail

Selection begins with microbiological verification: material is collected from the outbreak, the strain is isolated, its clinical significance and resistance are confirmed, and then a panel of phages is tested for sensitivity. Success is higher if the phage delivery matches the pathogen niche and if the titer is sufficient. [11]

When starting empirically without laboratory selection, the risk of non-response is higher. In such a situation, it is reasonable to organize strain isolation and selection in parallel, so that the cocktail can be replaced with a more effective one if necessary. [12]

The patient must meet the criteria for clinical appropriateness: proven bacterial origin, presence of a deliverable lesion, failure of standard regimens or impossibility of their use, willingness to co-administer with an antibiotic if this will improve penetration and biofilm control. [13]

Additional factors are assessed: immune status, extent of surgical debridement, possibility of repeat administrations, titer monitoring, and clinical dynamics. The more precise the route, the higher the likelihood of success. [14]

Table 3. Patient selection and laboratory route

Stage	What are we doing?	For what
We confirm the pathogen	Sowing, identification, resistome	Eliminate contamination and associated species
Testing the phage panel	Lysis on patient strain	Selecting active phages for a cocktail
We are planning delivery	Route of administration taking into account the lesion	Increase phage deposition in the desired niche
Preparing a cocktail	Several phages against a strain	Reduce the risk of resistance and expand coverage

How to prescribe: routes of administration, regimens and courses

The route of administration is selected based on the location: locally to the wound, instillation into a cavity, inhalation for the respiratory tract, orally for intestinal lesions, and intravenously for systemic and deep infections. The closer the delivery to the lesion, the higher the chance of phage contact with the target. [15]

The recommended course of treatment for acute local infections is typically 7-14 days with repeated doses. For bone and implant infections, longer regimens are used with a phased strategy: an intensive phase daily, followed by maintenance at intervals under clinical and microbiological monitoring. Details depend on the titer, tissue response, and concurrent surgery. [16]

The titer is expressed in plaque-forming units (PFU). In practice, high titers are sought in the prepared form, and the frequency of administration is determined to ensure stable phage presence in the lesion. Cocktail rotation or component replacement is appropriate if there are signs of decreased activity. [17]

The antibiotic combination is tailored to the specific needs of the patient: sometimes maintenance doses are sufficient to disrupt the biofilm and improve phage access, while in other cases, a full antibacterial regimen is required for the entire course. Synergy can reduce the bacterial load faster than either agent alone. [18]

Table 4. Routes of introduction and course guidelines

Path	Where appropriate	Administration frequency	Notes
Apply locally to the wound	Chronic ulcers, diabetic foot	1-2 times a day	Combine with debridement and dressings
Instillations	Cavities, sinus tracks, uro-niche	1-2 times a day	Control of drainage and retention
INHALATION	Respiratory tract	1-2 times a day	Specialized delivery, sediment control
Orally	Intestinal foci	2-3 times a day	Protection from acidic environment according to the center's protocol
Intravenously	Deep and systemic	According to the center's plans	Monitoring reactions and titers in the blood
Summary guidelines for clinical series and protocols of phage therapy centers. [19]

Phages and antibiotics: when together are better

The synergy between phages and antibiotics is manifested through several mechanisms: the antibiotic disrupts cellular barriers and metabolism, facilitating phage replication, while the phages reduce bacterial populations and the sensitivity of biofilms to molecules. For a number of species, a reduction in minimum inhibitory concentrations and accelerated biofilm clearance have been demonstrated. [20]

Experimental and applied research in 2025 updated the picture of PAS against Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter, and Escherichia coli. Practical conclusion: combination regimens are particularly useful for biofilms, prosthesis-associated lesions, and deep-seated niches. [21]

The laboratory selects the pairing based on the patient's strain. Not all combinations are created equal: antagonism may occur with incorrect sequence or dosage. Therefore, it is recommended to test the regimen and administration order on the patient's strain in advance. [22]

Clinically, this appears to be a phased strategy: debridement and local phage instillations initially, followed by the addition of a systemic antibiotic, or vice versa—a short antibiotic loading phase followed by phage application to disrupt the biofilm. The specific order is determined by laboratory data. [23]

Table 5. Examples of clinically reasonable combinations

Pathogen	Context	What do they combine?	Expected effect
Pseudomonas aeruginosa	Wound, airway, implant	Phage cocktail plus beta-lactam according to sensitivity	Accelerated cleaning, impact on biofilm
Staphylococcus aureus	Implant, osteomyelitis	Antistaphylococcal phages plus antistaphylococcal agent	Reduction of bacterial load and symptoms
Acinetobacter	Multidrug-resistant lesions	Phage cocktail plus sensitivity	Reducing the risk of relapse of a resistant clone
Sum of PAS reviews and applied research. [24]

Safety, immunogenicity, stability and quality control

Current data confirm a favorable safety profile for topical, instillation, inhalation, and intravenous administration. Adverse events are typically mild and transient. Product purity, absence of toxins, and reliable titer control are important. [25]

An immune reaction is possible, but clinically significant events are rare with proper quality and routing. Long-term courses and repeated administrations will require monitoring, and if activity declines, the cocktail will need to be updated to bypass antiphage responses and bacterial resistance. [26]

Quality control is now being formalized: in Europe, pharmacopoeial section 5.31 is in effect, and the EMA is promoting quality guidelines. This includes phage genetic characterization, contamination profiles, storage stability, and batch release standards. [27]

In the UK, the regulator has compiled a unified set of documents for phage products. This provides developers with a roadmap for production, control, and submission of documents. Harmonization of requirements will accelerate the transition from isolated cases to predictable programs. [28]

Table 6. What to monitor in the phage preparation before administration

Parameter	Why is it important?	Where does the requirement come from?
Identity and genomic purity	Eliminate unwanted genes	Pharmacopoeia and draft guidelines
Titer and stability	Ensure sufficient activity	Pharmacopoeia and regulatory requirements
Endotoxins and impurities	Reduce the risk of reactions	Quality and safety of series
Sterility and bioburden	Prevention of complications	Standards for the release of series
According to the European Pharmacopoeia and EMA documents. [29]

Legal access and routes: Europe, USA, UK

Europe. In 2024, the European Pharmacopoeia adopted General Section 5.31, establishing a framework for the production and control of phage products. In 2025, the EMA published draft guidelines on quality aspects of human phage-medicinal products. These are key steps towards legal and scalable use. [30]

USA. For patients with severe drug-resistant infections, access is possible through expanded access under Food and Drug Administration regulations. A physician submits an application, the manufacturing center provides a quality dossier and regimen, and treatment is then administered under supervision and reporting. [31]

The UK. The regulator has created a consolidated navigation system for phage product developers. This facilitates the design of manufacturing facilities and the submission of applications for clinical trials and individual programs. [32]

European initiatives on antimicrobial resistance highlight the potential of phage therapy and support the development of specific guidelines for human and veterinary practice, accelerating standardisation. [33]

Table 7. Where and how a patient can receive phage therapy today

Region	Access path	What is important to know
Europe	Clinical trials and individual programs in centers that comply with pharmacopoeial guidelines	Products of quality confirmed in accordance with section 5.31 are required.
USA	Expanded access under regulator control	A doctor's application and a quality dossier from the manufacturer are required.
United Kingdom	Research protocols and targeted programs	Rely on a set of regulatory materials for planning

Appointment practice

1. Confirm the clinically significant pathogen and the lesion. 2) Obtain material from the lesion and isolate the strain. 3) Test a panel of phages and select active ones. 4) Construct a cocktail of several phages. 5) Plan delivery taking into account the anatomy of the lesion. 6) Determine the course: duration, frequency, checkpoints. 7) Decide on a combination with an antibiotic based on laboratory data. 8) Ensure the quality of the drug in accordance with the pharmacopoeia and regulatory documents. 9) Monitor the clinical picture, microbiology, and safety. 10) If the response decreases, replace the cocktail component or reconsider the delivery route. [34]

Frequently asked questions about schemes and courses

How long does the course last? For superficial and cavitary lesions, 7-14 days with daily or twice-daily administrations is often sufficient. For bone and implant-associated infections, the course is longer and divided into intensive and maintenance phases, with periodic reviews based on progress. This is individualized. [35]

What is the optimal frequency of administration? The one that maintains sufficient contact between the phage and the bacteria at the site of infection. For localized infections, this is typically 1-2 times daily; for complex infections, more frequent instillations or combined delivery routes are possible. The decision is based on laboratory data and clinical evaluation. [36]

Is it always necessary to add an antibiotic? No. But in the case of biofilm, implantation, and deep niches, the combination increases the chances of success due to synergy and the disruption of resistance structures. The choice of molecule and the order of administration are tested on the patient's strain. [37]

How is quality controlled? According to the pharmacopoeial section and draft guidelines: phage identity and genomic purity, titer, endotoxins, sterility, and stability. Batches without these parameters are not released. [38]

What not to do

Do not proceed blindly without microbiological verification and selection—risk of failure and selection of resistance. Do not ignore surgical debridement if the lesion requires mechanical removal of dead tissue and drainage. Do not use products of questionable origin, lacking quality and traceability. Do not rely on universal ready-made mixtures without confirmed activity against the patient's strain. [39]